MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive ...

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time). A copy of the presentation covering information being discussed is available on the Company's website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors ...

Sales Highlights: Global • September 2024 Quarter AUD$1.5 million up 13% on prior quarter September 2024 Quarter AUD$1.0 million up 3% on prior quarter | --- | --- | |---------------|-------| | | | | Australia | | | North America | • | September 2024 Quarter AUD$0.5 million up 48% on prior quarter MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales ...

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Cam ...

公司概况 - 公司成立于1994年，总部位于澳大利亚[170] - 公司主要从事开发和商业化口服靶向多克隆抗体治疗炎症和感染性疾病[171] - 公司目前在澳大利亚销售两款主要商品Travelan®和Protectyn®[171] - 公司拥有三家全资子公司[275] - 公司的主要办公地点位于澳大利亚维多利亚州[276] - 公司认为现有设施能够满足当前需求[276] 产品和研发管线 - 公司未来3年将继续推进3个口服多克隆抗体药物候选物的临床开发[171] - 公司正在为Travelan®在美国获得生物制品许可申请(BLA)进行临床试验[184][185] - 公司的IMM-529候选药物针对难治性克罗斯氏菌感染症(CDI)具有独特的三重作用机制[189][190] - IMM-529可在预防感染、治疗原发性疾病和复发等所有疾病阶段显示出有效性[192] - IMM-529是一种口服疗法,可降低患者、医院和整个医疗系统的成本/负担[192] - IMM-529不是一种抗生素,它只针对C. difficile及其毒素B、孢子和营养细胞,因此不会对其他肠道菌群产生负面影响[192] - 公司正在开发IMM-529用于治疗复发性克罗氏菌感染(CDI),已完成临床前准备工作,计划于2025年上半年提交IND申请并开展II期临床试验[223,224] - IMM-529可靶向克罗氏菌毒素、芽胞和营养细胞,不会破坏肠道菌群,是一种革命性的CDI治疗方法[232] - 公司与Monash University合作开发并广泛进行了前期临床试验的IMM-529，针对难治性肠炎的毒素B、芽胞和营养细胞采取了三管齐下的独特方法，在预防原发性疾病、治疗原发性疾病和抑制复发等三个阶段均显示出治疗潜力[233] - IMM-529在多项前期动物模型试验中取得了令人鼓舞的结果，包括预防感染约70%存活率、治疗约80%存活率、复发抑制约90%存活率等[235] - 公司于2018年底在以色列两家临床中心启动了IMM-529的I/IIa期临床试验，但由于入组患者数量不足,公司决定关闭这些试验点,并计划与FDA沟通,重新制定IMM-529的临床开发计划[238,239] 与美国政府的合作 - 公司与美国国防部合作开展多项抗感染性疾病的研究[183] - 公司正在与美国海军医学研究司令部合作,开发和临床评估一种新的治疗药物,以预防对军人造成中度至重度的肠道感染[195,201,202] - 公司已获得美国食品药品监督管理局(FDA)批准,对这种新的口服治疗药物进行临床试验[202,205] - 公司获得了480万澳元(约343万美元)的资金,用于开发一种适合美国军方使用的Travelan®剂量方案[207] - 公司与美国国防部签订新的研究协议,旨在测试和确认Travelan®单次大剂量疗法在ETEC感染模型中的疗效[211] - 公司与美国国防部进行多次关键会议,讨论III期临床试验策略、FDA审评问题以及潜在的临床试验地点[212] - 公司提交了完整的研究提案,并获得美国政府赞助方的选中,正在与美国国防部就未来资助进行积极讨论[213] - 公司与美国陆军大学合作,计划进行一项随机双盲安慰剂对照的多中心临床试验,评估Travelan®预防旅行者腹泻的疗效[214,215,216] 产品销售和收入情况 - 公司计划继续投资和扩大Travelan和Protectyn在全球范围内的销售[175] - 公司的Travelan产品在预防和治疗志贺菌感染方面显示出良好的疗效,在美国作为膳食补充剂销售,在加拿大作为天然健康产品销售,在澳大利亚作为处方药销售[250,251,252] - 公司2024财年Travelan和Protectyn的全球销售额增长172%,达到490.3万澳元,其中美国市场Travelan销售增长67%,达到107.6万澳元[254] - 公司收入从2023财年的180.47万澳元增加到2024财年的490.29万澳元，增长172%[284] - 公司在澳大利亚和美国市场的Travelan®产品销售有所恢复，主要是由于国际旅行持续增加[285] - 公司预计Travelan®产品的销售收入将继续增加[285] 财务情况 - 公司获得了764,981澳元的澳大利亚研发税收优惠补助[285] - 公司获得了2,599,458澳元的MTEC研发补助[285] - 公司在2024财年确认了768,370美元的其他收入项目，同时抵消了上一期过度估计的3,339美元(2023年:392,877美元)，以系统地将R&D税收激励与其旨在补偿的成本相匹配[286] - 公司在2024财年获得了2,599,458美元(2023年:2,158,936美元)的MTEC研发补助金，并获得了28,000美元的EMDG出口市场开发补助金(2023年:28,000美元)[287] - 2024财年的收入为4,902,865美元，较2023财年的1,804,705美元增加了3,098,160美元，毛利率从73%下降到68%[289] - 2024财年的研发费用增加了2,783,316美元，销售和营销费用增加了1,102,225美元[290,291] - 2024财年的净亏损为6,936,957美元，较2023财年的3,786,507美元增加了3,150,450美元[295] - 公司于2020年7月完成了2000万美元

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline Insight, 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administr ...

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is p ...

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA. The focus of ...

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questio ...

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questio ...